Endovenous therapies for the treatment of symptomatic

AAGSVs demonstrated early outcomes similar to those of
patients with symptomatic GSV reï¬‚ux.57,169 For standalone
ablations, the revised VCSSs were similar between the
groups before and after the procedure; however, the CIVIQ20 scores had returned to the preintervention levels for
patients who had undergone standalone ablation of the
AAGSV at 6 months, suggesting